Get started
Author

Charles Le

Observed institution: Theriva Biologics (United States)
ORCID: 0009-0007-5110-1185
Observed ORCID: 0009-0007-5110-1185
OpenAlex ID: A5148899805
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
2017 · John Kokai-Kun, Tracey Roberts, et al. · Open Forum Infectious Diseases · 8
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al. · Clinical Cancer Research · 4
1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance
2018 · John Kokai-Kun, Charles Le, et al. · Open Forum Infectious Diseases · 2
SYN-004 (Ribaxamase) Protects the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment
2017 · John Kokai-Kun, Sheila Connelly, et al. · Open Forum Infectious Diseases · 2
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial
2026 · Rocio Garcia-Carbonero, Roberto Pazo Cid, et al. · Nature Medicine
Table S5 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S6 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S3 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S11 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S6 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S10 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S7 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S4 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S8 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S9 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S9 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S1 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S1 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S4 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Supplementary Text 1 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S2 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S2 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S5 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S3 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Data from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Works count: 29
Citation count: 16
H-index: 2
I10-index:
Year
Topic
Type